Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases

被引:612
作者
Gabriel, Sherine E. [1 ]
Michaud, Kaleb [2 ,3 ]
机构
[1] Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA
[2] Univ Nebraska, Med Ctr, Nebraska Arthrit Outcomes Res Ctr, Omaha, NE 68198 USA
[3] N Emporia, Natl Data Bank Rheumat Dis, Wichita, KS 67214 USA
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; PRIMARY SJOGRENS-SYNDROME; NECROSIS-FACTOR-ALPHA; GIANT-CELL ARTERITIS; BONE-MINERAL DENSITY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MODIFYING ANTIRHEUMATIC DRUGS; INTERSTITIAL LUNG-DISEASE; EARLY INFLAMMATORY POLYARTHRITIS; EVIDENT CARDIOVASCULAR-DISEASE;
D O I
10.1186/ar2669
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Epidemiology is the study of the distribution and determinants of disease in human populations. Over the past decade there has been considerable progress in our understanding of the fundamental descriptive epidemiology (levels of disease frequency: incidence and prevalence, comorbidity, mortality, trends over time, geographic distributions, and clinical characteristics) of the rheumatic diseases. This progress is reviewed for the following major rheumatic diseases: rheumatoid arthritis (RA), juvenile rheumatoid arthritis, psoriatic arthritis, osteoarthritis, systemic lupus erythematosus, giant cell arteritis, polymyalgia rheumatica, gout, Sjogren's syndrome, and ankylosing spondylitis. These findings demonstrate the dynamic nature of the incidence and prevalence of these conditions - a reflection of the impact of genetic and environmental factors. The past decade has also brought new insights regarding the comorbidity associated with rheumatic diseases. Strong evidence now shows that persons with RA are at a high risk for developing several comorbid disorders, that these conditions may have atypical features and thus may be difficult to diagnose, and that persons with RA experience poorer outcomes after comorbidity compared with the general population. Taken together, these findings underscore the complexity of the rheumatic diseases and highlight the key role of epidemiological research in understanding these intriguing conditions.
引用
收藏
页数:16
相关论文
共 201 条
[61]  
Gäre BA, 1999, CLIN EXP RHEUMATOL, V17, P367
[62]   Rofecoxib for rheumatoid arthritis [J].
Garner, S ;
Fidan, D ;
Frankish, R ;
Judd, M ;
Towheed, T ;
Wells, G ;
Tugwell, P .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)
[63]  
Gladman DD, 1998, ARTHRITIS RHEUM-US, V41, P1103, DOI 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO
[64]  
2-N
[65]  
Goldstein JL, 2000, AM J GASTROENTEROL, V95, P1681
[66]   Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection [J].
Gomez-Reino, Juan J. ;
Carmona, Loreto ;
Descalzo, Miguel Angel .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (05) :756-761
[67]   The widening mortality gap between rheumatoid arthritis patients and the general population [J].
Gonzalez, Angel ;
Kremers, Hilal Maradit ;
Crowson, Cynthia S. ;
Nicola, Paulo J. ;
Davis, John M., III ;
Therneau, Terry M. ;
Roger, Veronique L. ;
Gabriel, Sherine E. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (11) :3583-3587
[68]  
González-Gay MA, 1999, J RHEUMATOL, V26, P1326
[69]   Mortality in early inflammatory polyarthritis - Cardiovascular mortality is increased in seropositive patients [J].
Goodson, NJ ;
Wiles, NJ ;
Lunt, M ;
Barrett, EM ;
Silman, AJ ;
Symmons, DPM .
ARTHRITIS AND RHEUMATISM, 2002, 46 (08) :2010-2019
[70]  
GREEN L, 1988, J RHEUMATOL, V15, P110